New treatments for genotype 1 chronic hepatitis C – focus on simeprevir

References

• DitahIDitahFDevakiPThe changing epidemiology of hepatitis C virus infection in the United States: national health and nutrition examination survey 2001 through 2010J Hepatol201460469169824291324
   PubMed Web of Science ®Google Scholar
• FenoglioLSerrainoCCastagnaEEpidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma casesWorld J Gastroenterol201319213207321623745022
   PubMed Web of Science ®Google Scholar
• KimMNKimBKHanKHHepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia–Pacific regionJ Gastroenterol201348668168823463401
   PubMed Web of Science ®Google Scholar
• OmataMKandaTYuMLAPASL consensus statements and management algorithms for hepatitis C virus infectionHepatol Int201262409435
   PubMed Web of Science ®Google Scholar
• SeeffLBNatural history of chronic hepatitis CHepatology2002365 Suppl 1S35S4612407575
   PubMed Web of Science ®Google Scholar
• TakanoSYokosukaOImazekiFTagawaMOmataMIncidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patientsHepatology19952136506557875662
   PubMed Web of Science ®Google Scholar
• KandaTImazekiFYokosukaONew antiviral therapies for chronic hepatitis CHepatol Int20104354856121063477
   PubMed Web of Science ®Google Scholar
• KandaTNakamotoSNakamuraMDirect-acting antiviral agents for the treatment of chronic hepatitis C virus infectionJ Clin Transl Hepatol20142116
   PubMedGoogle Scholar
• D’AmbrosioRColomboMSafety of direct antiviral agents in real lifeDig Liver Dis201345Suppl 5S363S36624091117
   PubMedGoogle Scholar
• KumadaHToyotaJOkanoueTChayamaKTsubouchiHHayashiNTelaprevir with peginterferon and ribavirin for treatment-naïve patients chronically infected with HCV of genotype 1 in JapanJ Hepatol2012561788421827730
   PubMed Web of Science ®Google Scholar
• TsantrizosYSTMC-435, an NS3/4A protease inhibitor for the treatment of HCV infectionCurr Opin Investig Drugs2009108871881
   PubMedGoogle Scholar
• RosenquistASamuelssonBJohanssonPODiscovery and development of simeprevir (TMC435), a HCV NS3/4A protease inhibitorJ Med Chem20145751673169324446688
   PubMed Web of Science ®Google Scholar
• LinTILenzOFanningGIn vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitorAntimicrob Agents Chemother20095341377138519171797
   PubMed Web of Science ®Google Scholar
• MorenoCBergTTanwandeeTAntiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2–6: TMC435-C202, a Phase IIa, open-label studyJ Hepatol20125661247125322326470
   PubMed Web of Science ®Google Scholar
• LenzOVijgenLBerkeJMVirologic response and characterisation of HCV genotype 2–6 in patients receiving TMC435 monotherapy (study TMC435-C202)J Hepatol201358344545123142061
   PubMed Web of Science ®Google Scholar
• WuSKandaTNakamotoSImazekiFYokosukaOHepatitis C virus protease inhibitor-resistance mutations: our experience and reviewWorld J Gastroenterol201319478940894824379619
   PubMed Web of Science ®Google Scholar
• LenzOVerbinnenTLinTIIn vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435Antimicrob Agents Chemother20105451878188720176898
   PubMed Web of Science ®Google Scholar
• HalfonPLocarniniSHepatitis C virus resistance to protease inhibitorsJ Hepatol201155119220621284949
   PubMed Web of Science ®Google Scholar
• XueWPanDYangYLiuHYaoXMolecular modeling study on the resistance mechanism of HCV NS3/4A serine protease mutants R155K, A156V and D168A to TMC435Antiviral Res201293112613722127068
   PubMed Web of Science ®Google Scholar
• LenzOde BruijneJVijgenLEfficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapyGastroenterology201214351176117822885330
   PubMed Web of Science ®Google Scholar
• FriedMWButiMDoreGJOnce-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyHepatology20135861918192923907700
   PubMed Web of Science ®Google Scholar
• HayashiNSetoCKatoMKomadaYGotoSOnce-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON studyJ Gastroenterol201449113814724005956
   PubMed Web of Science ®Google Scholar
• WuSKandaTNakamotoSPrevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific regionPLoS One201389e7361524069214
   PubMed Web of Science ®Google Scholar
• ZeuzemSBergTGaneESimeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a Phase IIb trialGastroenterology2014146243044124184810
   PubMed Web of Science ®Google Scholar
• HayashiNIzumiNKumadaHSimeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trialJ Hepatol Epub201449
   Web of Science ®Google Scholar
• IzumiNHayashiNKumadaHOnce-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studiesJ Gastroenterol201449594195324626851
   PubMed Web of Science ®Google Scholar
• SuzukiFHayashiNGotoSKumadaHSimeprevir with Peginterferon alpha-2b/Ribavirin for hepatitis C genotype 1 patients: the CONCERTO-4 studyKanzo201454suppl1A157 Japanese
   Google Scholar
• JacobsonIMDoreGJFosterGRSimeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST-1 and 2 Phase III trials [abstract]Hepatology201358Suppl 1756A
   Google Scholar
• FornsXLawitzEZeuzemSSimeprevir (TMC435) with peginterferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection inpatients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE Phase III trial [abstract]Hepatology201358Suppl 1737A
   Google Scholar
• Janssen R&D IrelandTMC435HPC3001 – an efficacy, safety and tolerability study for TMC435 vs telaprevir in combination with pegINFα-2a and ribavirin in chronic hepatitis C patients who were null or partial responders to prior pegINFα-2a and ribavirin therapy (ATTAIN) Available from: http://clinicaltrials.gov/ct2/show/NCT01485991. NLM identifier: NCT01485991Accessed February 10, 2014
   Google Scholar
• JacobsonIMGhalibRHRodriguez-TorresMSVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: the COSMOS study [abstract]Hepatology201358Suppl 61379A
   Web of Science ®Google Scholar
• KandaTYokosukaOOmataMAntiviral therapy for “difficult-to-treat” hepatitis C virus-infected patientsChin Med J (Engl)2013126234568457424286427
   PubMed Web of Science ®Google Scholar
• SulkowskiMSHCV therapy in HIV-infected patientsLiver Int201333Suppl 1636723286848
   PubMed Web of Science ®Google Scholar
• Perez-LatorreLSanchez-CondeMRinconDPrediction of liver complications in patients with hepatitis C virus-related cirrhosis with and without HIV coinfection: comparison of hepatic venous pressure gradient and transient elastographyClin Infect Dis201458571371824265358
   PubMed Web of Science ®Google Scholar
• TorrianiFJRodriguez-TorresMRockstrohJKPeginterferon α-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patientsN Engl J Med2004351543845015282351
   PubMed Web of Science ®Google Scholar
• ChungRTAndersenJVolberdingPPeginterferon α-2a plus ribavirin versus interferon α-2a plus ribavirin for chronic hepatitis C in HIV-coinfected personsN Engl J Med2004351545145915282352
   PubMed Web of Science ®Google Scholar
• CarratFBani-SadrFPolSPegylated interferon α-2b vs standard interferon α-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trialJAMA2004292232839284815598915
   PubMed Web of Science ®Google Scholar
• LagunoMMurillasJBlancoJLPeginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for treatment of HIV/HCV co-infected patientsAIDS20041813F27F3615316335
   PubMed Web of Science ®Google Scholar
• SulkowskiMSShermanKEDieterichDTCombination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trialAnn Intern Med20131592869623685940
   PubMed Web of Science ®Google Scholar
• SulkowskiMPolSMallolasJBoceprevir versus placebo with pegylated interferon α-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled Phase 2 trialLancet Infect Dis201313759760523768747
   PubMed Web of Science ®Google Scholar
• Martel-LaferriereVBrinkleySBichoupanKVirological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfectionHIV Med201415210811524025147
   PubMed Web of Science ®Google Scholar
• FiererDSDieterichDTMullenMPTelaprevir in the treatment of acute hepatitis C virus infection in HIV-infected menClin Infect Dis201458687387924336914
   PubMed Web of Science ®Google Scholar
• HighleymanLEACS 2013: simeprevir with interferon effective for genotype 1 HIV/HCV coinfected people [webpage on the Internet]San Francisco, CAhivandhepatitis.com2013 [cited October 20, 2013]. Available from: http://www.hivandhepatitis.com/hcv-treatment/experimental-hcv-drugs/4367-eacs-2013-simeprevir-with-interferon-effective-for-hivhcv-coinfected-people-with-genotype-1-or-4Accessed February 10, 2014
   Google Scholar
• DonlinMJCannonNAYaoEPretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapyJ Virol200781158211822417522222
   PubMed Web of Science ®Google Scholar
• AkutaNSuzukiFHirakawaMA matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological responseJ Med Virol200981345245819152407
   PubMed Web of Science ®Google Scholar
• AlestigEArnholmBEilardACore mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infectionBMC Infect Dis20111112421569441
   PubMed Web of Science ®Google Scholar
• SorianoVPovedaEVispoELabargaPRallonNBarreiroPPharmacogenetics of hepatitis CJ Antimicrob Chemother201267352352922194301
   PubMed Web of Science ®Google Scholar
• NakamotoSImazekiFFukaiKAssociation between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma developmentJ Hepatol2010521727819910070
   PubMed Web of Science ®Google Scholar
• MaekawaSEnomotoNOnce-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis CJ Gastroenterol201449116316424356811
   PubMed Web of Science ®Google Scholar